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Abstract: 
Endovascular aneurysm repair (EVAR) is a well-established minimally invasive technique that relies 
on x-ray guidance to introduce a stent through the femoral artery and manipulate it into place.  The 
aim of this study was to estimate patient organ and effective doses from EVAR procedures using 
anatomically realistic computational phantoms and detailed exposure information from radiation dose 
structured reports (RDSR). Methods: Lookup tables of conversion factors relating kerma area product 
(PKA) to organ doses for 49 different beam angles were produced using Monte Carlo simulations 
(MCNPX2.7) with ICRP adult male and female voxel phantoms for EVAR procedures of varying 
complexity (infrarenal, fenestrated/branched and thoracic EVAR). Beam angle specific correction 
factors were calculated to adjust doses according to x-ray energy. A MATLAB function was written 
to find the appropriate conversion factor in the lookup table for each exposure described in the RDSR, 
perform energy corrections, and multiply by the respective exposure PKA. Using this approach, organ 
doses were estimated for 183 EVAR procedures in which RDSRs were available. A number of 
simplified dose estimation methodologies were also investigated for situations in which RDSR data 
are not available. Results: Mean estimated bone marrow doses were 57 (range: 2-247), 86 (2-328) and 
54 (8-250) mGy for infra-renal, fenestrated/branched and thoracic EVAR respectively. Respective 
effective doses were 27 (1-208), 54 (1-180) and 37 (5-167) mSv. Dose estimates using non-
individualised, average conversion factors, along with those produced using the alternative Monte 
Carlo code PCXMC, yielded reasonably similar results overall, though variation for individual 
procedures could exceed 100% for some organs. In conclusion, radiation doses from x-ray guided 
endovascular aneurysm repairs are potentially high, though this must be placed in the context of the 
life sparing nature and high success rate for this procedure. 
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Introduction: 
Aortic aneurysms occur when a section of the blood vessel wall weakens, allowing a balloon-like 
bulge to develop. Rupture of aortic aneurysms usually result in catastrophic haemorrhage and death 
(Albert Einstein was a notable sufferer). Even if the patient makes it alive to hospital, emergency 
surgery for a ruptured aneurysm can have a mortality as high as 70% (1). The preferred management 
for known aneurysms, once they reach a threshold size, is to carry out elective repair to circumvent 
the risk of rupture. Endovascular aortic aneurysm repair (EVAR) is a minimally invasive technique 
that offers the chance to reline the aorta from within, using a stent graft, thus excluding the aneurysm 
from the circulation. The procedure relies on the use of x-ray guidance to introduce and manipulate 
the stent graft within the aorta. As experience with this technique has increased, so has the complexity 
of repairs performed, some involving the use of multiple stent components during procedures lasting 
several hours. This has recently focused attention on the possible deleterious effects of the consequent 
radiation exposure, including studies that have suggested an increased risk of malignancy in patients 
after EVAR, but this evidence is by no means conclusive (2, 3). 
Due to the procedural complexity, and the thickness and density of the abdominal region, EVAR has 
the potential to deliver particularly high radiation doses. Air kerma at the entrance skin surface may 
reach several gray (Gy), while kerma area product (PKA) frequently exceeds several hundred Gy cm
2 
(4-6). Aside from these simple dose indicators, published estimates of patient dose have been almost 
entirely restricted to effective dose. Figures are typically in the range 10-100 mSv (4, 5, 7-11), though 
figures of up to 1000 mSv have been reported (4). All estimates of effective dose have been obtained 
using the Monte Carlo code PCXMC (STUK, Helsinki, Finland) (12). The deficiencies of the 
modified Oak Ridge National Laboratories (ORNL) phantom models (13) used in PCXMC are well 
known (e.g. (14)). Organ shapes are very simplistic and there are no separate male and female 
phantoms. Furthermore, although EVAR procedures involve a range of beam angles, no evaluation of 
the impact of beam angle on organ doses appears to have been performed. Information on organ doses 
from EVAR is currently very limited.  
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We sought to address these limitations by using a Monte Carlo (MC) approach to estimate organ 
doses with realistic phantom models and incorporating detailed information on beam angles and x-ray 
beam spectra.  The study utilised a ‘lookup table’ methodology in which a library of conversion 
factors relating input dose (PKA) to various organ doses is produced for a wide range of conditions. 
Doses can then be estimated without needing to perform new simulations by matching exposure 
conditions to the appropriate conversion factor. 
 
Procedure description: 
The term ‘EVAR’ is used to refer to a group of procedures of varying complexity used to treat 
aneurysms of the aorta.  The simplest of these is the infra-renal EVAR (IEVAR), which is used when 
the aneurysm affects the lower portion of the aorta below the renal arteries (supplying the kidneys).  
IEVAR was the first of these procedures to be developed and is the least time consuming, generally 
leading to the least radiation exposure.  Aneurysms involving the descending thoracic aorta, above the 
coeliac trunk, are treated with a thoracic EVAR (TEVAR) (15). These are difficult procedures, 
associated with higher mortality and risk of stroke and spinal cord ischaemia (16).  The central portion 
of the aorta, in the upper abdomen, gives rise to the coeliac trunk, the superior mesenteric artery and 
the renal arteries, vessels that supply much of the vital intra-abdominal organs. Unlike stent grafts 
used for IEVAR and TEVAR, devices used in this region are especially designed to allow the 
aforementioned vessels to be incorporated in the repair, making repair of aneurysms in this aortic 
much more complex.  Fenestrated EVAR (FEVAR) describes the situation where the fabric of the 
stent graft covers the aorta adjacent to one or more of these arteries (target vessels), but perfusion is 
maintained through accurately placed windows (fenestrations) in the fabric directly in front of the 
orifice of the target vessel (15).  Branched EVAR (BEVAR) is when these vital arteries arise from the 
dilated aneurysmal segment of the aorta and therefore there is a gap between the stent graft and the 
aortic wall with its branches (15).  This gap needs to be bridged with further stents into the target 
vessels in order to maintain perfusion to the vital organs.  Due to the increased complexity, FEVAR 
and BEVAR are more time-consuming procedures involving more fluoroscopy time and digital 
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subtraction angiography (DSA) runs than IEVAR and TEVAR.  Therefore, they generally involve 
more radiation exposure to the patient (4, 17). 
 
Methods: 
Monte Carlo simulations were performed using the general purpose radiation transport code 
MCNPX2.7 (Los Alamos National Laboratory, New Mexico, USA) (18). Detailed specifications are 
provided in Appendix 1. We used the reference adult male and female voxel phantoms published by 
the International Commission on Radiological Protection (ICRP) (19). Both phantoms were created 
from cross sectional images of individuals who had undergone whole body CT scanning during 
treatment for leukaemia. Neither patient had any structural abnormality. The male phantom is based 
on a 38-year-old individual of height 178 cm and mass 70 kg. The female phantom is based on a 43-
year-old, of height 167 cm and mass 59 kg (19). A detailed specification of these phantoms is 
provided in Appendix 2. Both phantoms had their arms removed, to prevent any shielding effect for 
laterally orientated projections, and were placed on a table of 1 cm thickness, made of carbon (density 
= 1.4 g cm-3).  
An isocentric coordinate system was developed to calculate the source position, source direction 
vector and collimator window position and orientation for any specified beam angle, centring point 
and field size. The beam was collimated by means of two concentric spherical shells, of radius 64.5 
and 64.6 cm, surrounding the patient. The phantom’s legs are partially outside the collimator shells in 
the model, although the dose to the excluded regions is close to zero. The region between the spheres 
was assigned an MCNP ‘importance’ of zero, meaning that the histories of any particles entering this 
region were terminated. The source was placed outside the collimator spheres at a distance of 75 cm 
from the isocentre. This distance was representative of clinical exposure conditions. An output 
window, which also served as a PKA meter, was placed to allow x-rays to pass through the collimator 
spheres and irradiate the required region (Figure 1). The size of the output window was adjusted to 
irradiate the region of interest, depending on the specific type of EVAR:  
• IEVAR: Between the renal arteries and just below the bifurcation of the aorta (Figure 2) 
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• FEVAR/BEVAR: the whole abdominal aorta, from the diaphragm to just below the 
bifurcation 
• TEVAR: whole thoracic aorta, from the lung apices to the diaphragm 
The source was forward biased, along its direction vector, to expose a region slightly larger than the 
collimator window. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Irradiation geometry looking along patient long axis from head to foot. Note: not drawn to scale! 
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lateral) 
0° (PA) 
90° LAO (left 
lateral) 
30° RAO 
Collimator spheres 
Source 60° RAO 
Window/PKA meter  
Zero importance 
region 
𝜑 
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Figure 2: Mid-sagittal and coronal view of female ICRP phantom with superimposed photon mesh tally showing exposed 
field for infra-renal EVAR. 
 
Only photons were transported in the MCNP simulations, meaning secondary electrons were not 
tracked and all energy was assumed to be deposited locally. This greatly improved the computational 
efficiency of the calculations. Given the relatively low photon energies used in simulations (up to 120 
keV), the range of secondary electrons would seldom exceed 100 μm in water (20), thus this 
approximation can be considered reasonable. Doses were calculated by MCNPX for all organs using 
the f6 tally with the equivalence between dose and kerma assumed explicitly from the assumption of 
secondary charged particle equilibrium. The conversion factor (CF) relating PKA to organ dose D 
(𝐶𝐹𝑃𝐾𝐴→𝐷), in mGy/Gy cm
2 between absorbed dose to each organ and PKA was calculated as: 
𝐶𝐹𝑃𝐾𝐴→𝐷 =
1000 × 𝑇𝑂
𝑇𝑊 × 𝐴𝑊
 
Where 𝐴𝑊 is the area of the collimator window (in cm
2) normal to the beam central axis, 𝑇𝑂 is the 
dose tally (in MeV/g) to the organ and 𝑇𝑊 is the dose tally, in air, to the window cell. For each 
simulation, 107 photons were tracked. This resulted in MC simulation statistical uncertainties of well 
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below 5% for all in-field and beam bordering organs considered in this study and for all organs 
making a meaningful contribution to effective dose. Non-statistical, or systematic uncertainties in the 
modelling are harder to estimate, though it is noted that MCNP is very well benchmarked for the 
types of exposure of current interest (18). 
Active bone marrow dose was calculated by scoring absorbed dose within the spongiosa regions in 
different bone sites, weighted by the bone site-specific distribution of active bone marrow (21).  ICRP 
Publication 116 (22) notes that this approach provides reasonable estimation of the values calculated 
from dose response functions. 
Monte Carlo simulations were used to create a lookup table of 𝐶𝐹𝑃𝐾𝐴→𝐷 conversion factors for 49 
different beam angles, as described below. Different lookup tables were created for each of 17 organs 
and tissues. The x-ray beam may be angulated around the patient in the axial plane, denoted 𝜑, and in 
the cranio-caudal direction (head to foot), denoted 𝜗 (Figures 1, 3). Simulations were performed in the 
range 𝐶𝑅𝐴45° ≤ 𝜗 ≤ 𝐶𝐴𝑈45° in 15° intervals and 𝐿𝐴𝑂90° ≤ 𝜑 ≤ 𝑅𝐴𝑂90° in 30° intervals 
(CRA/CAU = cranial/caudal, RAO/LAO = right/left anterior oblique). This process was performed 
for both male and female phantoms, and for seven different x-ray spectra, calculated using Spekcalc 
(23) (Table 1). These spectra were based on a range of combinations of tube potential and added 
copper filtration typical of clinical practice, as determined from a sample of radiation dose structured 
reports (discussed below). For each of the 49 different beam angles, a 2nd degree polynomial was 
fitted to the relationship between half value layer (HVL), also calculated using Spekcalc, and organ 
dose, relative to a HVL of 7.08 mm (representing 80 kV and 0.4 mm Cu). This choice of ‘reference’ 
HVL was arbitrary and makes no difference. 
 
 
 
 
 
Figure 3: Irradiation geometry for cranio-caudal beam angulation. CRA = cranial angulation, CAU = caudal angulation 
 
 45° CAU         0°        45° CRA  
𝜗 
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Table 1: Beam spectra used in simulations, defined by tube potential and added copper (Cu) and aluminium (Al) filtration. 
HVL = half value layer 
Spectrum 
Peak tube Cu 
(mm) 
Al 
(mm) 
1st HVL 
(mm Al) potential (kVp) 
1 50 0.1 3.5 2.96 
2 60 0.4 3.5 5.3 
3 80 0.1 3.5 4.75 
4 80 0.4 3.5 7.08 
5 100 0.1 3.5 5.87 
6 100 0.4 3.5 8.46 
7 120 0.4 3.5 9.49 
 
A function was written in MATLAB (vR2018a, Mathworks, Natick, New Hampshire, USA) to pick 
the appropriate conversion factor from the lookup tables according to specified beam angle 
(combination of 𝜗 and 𝜑) and patient sex. For beam angles in between the simulated intervals, 
𝐶𝐹𝑃𝐾𝐴→𝐷 was calculated by linear interpolation. Initially, doses were calculated for the reference HVL 
of 7.08 mm, then adjusted to the specified HVL using the appropriate energy correction polynomial 
described above. Finally, the estimated dose for an exposure was calculated by multiplying the energy 
adjusted 𝐶𝐹𝑃𝐾𝐴→𝐷 by the respective exposure PKA.  
 
 
Dose estimates for clinical procedures: 
The lookup-table-based MATLAB function described above was used to estimate organ doses for a 
sample of clinical procedures. Fully anonymized radiation dose structured reports (RDSRs) were 
obtained for 183 EVAR procedures (81 IEVAR, 66 FEVAR/BEVAR and 36 TEVAR) performed 
using a Philips Allura Xper FD20 system (Philips Healthcare, Eindhoven, the Netherlands) between 
2017 and 2019. These RDSRs give information on all x-ray exposures (both fluoroscopy and digital 
acquisitions), including beam angle, tube potential (kVp), added filtration and PKA. For each exposure, 
the combination of kVp and added Cu filtration was converted to HVL in mm Al. The total 
examination dose for each organ was calculated as the sum of doses for all exposures described in the 
RDSR for that examination. 
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For the IEVAR procedures, we also investigated a number of simplified approaches to estimating 
doses for cases where RDSRs are not available. This allowed the potential errors to be evaluated that 
result from dose estimation using limited information, e.g. total examination PKA only. Firstly, organ 
doses for each procedure were divided by the total procedural PKA, giving a single 𝐶𝐹𝑃𝐾𝐴→𝐷 
conversion factor, taking into account all the various beam angles and x-ray spectra used throughout 
the procedure. The average ‘whole procedure’ conversion factor for all 81 IEVAR procedures was 
then calculated for each organ and used to estimate doses for individual procedures using total PKA. 
For the second approach, doses were estimated with 100% of PKA delivered in the PA projection, as is 
typically assumed in similar studies.   
As a further comparison, doses were also estimated using the alternative Monte Carlo code PCXMC 
(V2.0). PCXMC is well-suited to utilising RDSRs (e.g. (24, 25)) as data can be inputted into the 
‘Autocalc’ Excel spreadsheet with minimal preparation. Separate simulations were performed for 
each exposure listed in the RDSR, taking into account beam angle, kVp and filtration. Simulations 
were performed with 50,000 photons, which was sufficient to keep simulation MC uncertainties well 
below 5% for organs of interest. Field size and centring point were kept constant for each EVAR type. 
The modified ORNL phantom models used in PCXMC (13) do not feature an aorta, let alone the 
bifurcation or arch of this vessel, meaning defining an appropriate exposure region was challenging. 
 
Results: 
Estimated organ doses are shown in Tables 2-4 for IEVAR, FEVAR/BEVAR and TEVAR 
respectively. These organ doses are based on median PKA values of 75 Gy cm
2 (interquartile range: 
48-148) for IEVAR, 119 Gy cm2 (85, 209) for FEVAR/BEVAR and 110 Gy cm2 (50-165) for 
TEVAR. Tables 6-8 show average 𝐶𝐹𝑃𝐾𝐴→𝐷 conversion factors for each procedure type.  For the 
abdominal aorta EVAR procedures (IEVAR, BEVAR, FEVAR), doses were highest for the kidneys, 
pancreas, colon and small intestine. Estimated kidney doses exceeded 200 mGy for 19% of infra-
renal, 44% of FEVAR/BEVAR procedures. Active bone marrow (ABM) dose was also high, with 
mean doses exceeding 50 mGy for all procedure types. This is primarily due to the contribution of 
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marrow in the spine. Consequently, ABM dose tended to be higher for PA-orientated projections 
(Figure 4). Conversely, colon and kidney doses were higher for more laterally orientated projections.  
Table 2: Estimated organ doses (in mGy) for 81 infra-renal endovascular aneurysm repairs. STD = standard deviation, IQR 
= interquartile range, * females only 
Organ 
Estimated dose (mGy) 
Mean [STD] Median [IQR] Range 
Thyroid 0 [0] 0 [0, 1] 0 - 2 
Oesophagus 5 [5] 3 [2, 6] 0 - 20 
Lungs 4 [4] 2 [2, 5] 0 - 16 
Breasts* 1 [2] 1 [0, 1] 0 - 5 
Heart 5 [6] 3 [2, 6] 0 - 28 
Stomach 30 [46] 16 [9, 29] 1 - 279 
Liver 28 [42] 14 [8, 34] 0 - 329 
Gall bladder 52 [74] 28 [16, 62] 1 - 557 
Adrenals 69 [68] 44 [25, 96] 1 - 343 
Spleen 25 [33] 14 [8, 24] 1 - 151 
Pancreas 91 [103] 54 [33, 112] 2 - 473 
Kidneys 150 [184] 83 [46, 168] 4 - 983 
Small Intestine 77 [131] 37 [20, 77] 2 - 919 
Colon 73 [159] 26 [14, 61] 1 - 1095 
Urinary bladder 6 [7] 4 [2, 7] 0 - 32 
Active bone marrow 57 [55] 36 [24, 71] 2 - 247 
 
 
Table 3: Estimated organ doses (in mGy) for 66 fenestrated or branched endovascular aneurysm repairs. STD = standard 
deviation, IQR = interquartile range, * females only 
Organ 
Estimated dose (mGy) 
Mean [STD] Median [IQR] Range 
Thyroid 2 [1] 1 [1, 2] 0 - 6 
Oesophagus 29 [21] 23 [14, 41] 1 - 108 
Lungs 19 [13] 15 [10, 25] 0 - 65 
Breasts* 5 [4] 4 [3, 8] 1 - 12 
Heart 26 [19] 21 [14, 34] 1 - 88 
Stomach 95 [76] 80 [41, 113] 2 - 349 
Liver 96 [85] 70 [38, 112] 1 - 364 
Gall bladder 105 [89] 83 [46, 126] 2 - 398 
Adrenals 252 [188] 183 [134, 340] 5 - 959 
Spleen 185 [182] 138 [67, 245] 3 - 1064 
Pancreas 139 [105] 101 [69, 169] 3 - 520 
Kidneys 248 [201] 176 [125, 315] 3 - 963 
Small Intestine 91 [70] 72 [43, 112] 2 - 356 
Colon 87 [75] 65 [40, 108] 1 - 338 
Urinary bladder 5 [4] 4 [3, 6] 0 - 21 
Active bone marrow 86 [63] 64 [46, 115] 2 - 328 
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Table 4: Estimated organ doses (in mGy) for 36 thoracic endovascular aneurysm repairs. STD = standard deviation, IQR = 
interquartile range, * females only 
Organ 
Estimated dose (mGy) 
Mean [STD] Median [IQR] Range 
Thyroid 22 [22] 16 [8, 25] 4 - 100 
Oesophagus 103 [97] 86 [38, 118] 17 - 432 
Lungs 123 [124] 94 [43, 141] 14 - 576 
Breasts* 18 [17] 13 [8, 21] 4 - 65 
Heart 114 [110] 84 [37, 141] 17 - 469 
Stomach 24 [25] 18 [9, 26] 4 - 124 
Liver 27 [30] 18 [11, 30] 2 - 151 
Gall bladder 10 [10] 7 [3, 11] 1 - 49 
Adrenals 19 [20] 15 [7, 20] 3 - 101 
Spleen 45 [49] 29 [14, 49] 6 - 220 
Pancreas 8 [9] 6 [3, 10] 1 - 46 
Kidneys 9 [9] 6 [3, 10] 1 - 46 
Small Intestine 2 [2] 2 [1, 3] 0 - 12 
Colon 3 [3] 1 [1, 3] 0 - 17 
Urinary bladder 0 [0] 0 [0, 0] 0 - 1 
Active bone marrow 54 [54] 40 [21, 63] 8 - 250 
 
 
Effective dose could not be estimated directly as we did not calculate separate MCNP tallies for bone 
surfaces and lymph nodes. Using PCXMC, we determined that the inclusion of these two tissues 
increased effective dose by approximately 3%, relative to effective dose calculated without bone or 
lymph nodes. We were then able to estimate effective dose by multiplying the figures obtained 
without the contribution of bones and lymph nodes by a factor of 1.03. Using this approach, the mean 
estimated effective doses for IEVAR, FEVAR/BEVAR and TEVAR procedures were 27, 54 and 37 
mSv, respectively. Note that these ‘effective doses’ are sex-specific, rather than sex-averaged: 
although therefore not true effective dose, presentation of the data in this way is considered more 
insightful for the present purposes as a means of quantifying overall whole body exposures for the 
male and female separately. Of course, the ICRP advise against the use of true effective dose (26) for 
personalized dosimetry in any case. For abdominal region EVAR, effective dose was dominated by 
contributions from the colon, bone marrow, stomach and the ‘remainder’ category (including kidneys, 
gall bladder and small intestine).  
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Table 5: Average 𝐶𝐹𝑃𝐾𝐴→𝐷 𝑐onversion factors for organs (mGy/Gycm
2) and effective dose (mSv/Gycm2) for infra-renal 
EVAR. Note: effective dose is sex-specific.  
Organ 
Male Female 
Mean Range Mean Range 
Thyroid 0.00 [0-0.01] 0.00 [0-0.01] 
Oesophagus 0.04 [0.03-0.08] 0.03 [0.03-0.04] 
Lungs 0.03 [0.02-0.06] 0.04 [0.03-0.05] 
Breasts - - 0.01 [0.01-0.01] 
Heart 0.04 [0.03-0.07] 0.04 [0.03-0.05] 
Stomach 0.20 [0.14-0.59] 0.41 [0.27-0.89] 
Liver 0.19 [0.11-0.68] 0.35 [0.19-0.69] 
Gall bladder 0.37 [0.23-1.16] 0.65 [0.49-0.87] 
Adrenals 0.58 [0.32-1.35] 0.79 [0.41-1.30] 
Spleen 0.19 [0.05-0.52] 0.29 [0.17-0.62] 
Pancreas 0.71 [0.57-0.95] 1.01 [0.86-1.40] 
Kidneys 1.12 [0.74-2.04] 1.69 [1.24-2.29] 
Small Intestine 0.55 [0.36-1.94] 0.62 [0.46-1.29] 
Colon 0.44 [0.23-2.31] 0.57 [0.39-1.03] 
Urinary bladder 0.05 [0.04-0.09] 0.04 [0.04-0.06] 
Bone marrow 0.49 [0.33-0.66] 0.59 [0.49-0.67] 
Effective dose 0.20 [0.14-0.44] 0.28 [0.21-0.38] 
 
 
Table 6: Average 𝐶𝐹𝑃𝐾𝐴→𝐷 𝑐onversion factors for organs (mGy/Gycm
2) and effective dose (mSv/Gycm2) for 
fenestrated/branched EVAR. Note: effective dose is sex-specific.  
Organ 
Male Female 
Mean Range Mean Range 
Thyroid 0.01 [0.01-0.01] 0.01 [0.01-0.02] 
Oesophagus 0.18 [0.13-0.23] 0.21 [0.14-0.28] 
Lungs 0.11 [0.07-0.14] 0.19 [0.15-0.25] 
Breasts 0.03 [0.02-0.05] 0.05 [0.04-0.06] 
Heart 0.16 [0.11-0.23] 0.21 [0.12-0.37] 
Stomach 0.56 [0.30-0.99] 0.87 [0.31-1.98] 
Liver 0.51 [0.23-1.07] 1.05 [0.69-1.56] 
Gall bladder 0.57 [0.29-1.15] 1.06 [0.94-1.28] 
Adrenals 1.52 [1.12-1.96] 1.83 [1.64-2.10] 
Spleen 1.09 [0.29-3.15] 1.37 [0.31-4.52] 
Pancreas 0.83 [0.55-1.07] 1.05 [0.73-1.44] 
Kidneys 1.44 [0.87-2.14] 1.81 [1.35-2.96] 
Small Intestine 0.57 [0.35-1.04] 0.54 [0.29-1.00] 
Colon 0.55 [0.21-1.15] 0.46 [0.31-0.61] 
Urinary bladder 0.03 [0.02-0.07] 0.03 [0.02-0.03] 
Bone marrow 0.52 [0.39-0.69] 0.63 [0.51-0.71] 
Effective dose 0.32 [0.21-0.47] 0.42 [0.3-0.64] 
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Table 7: Average 𝐶𝐹𝑃𝐾𝐴→𝐷 𝑐onversion factors for organs (mGy/Gycm
2) and effective dose (mSv/Gycm2) for thoracic EVAR. 
Note: effective dose is sex-specific.  
Organ 
Male Female 
Mean Range Mean Range 
Thyroid 0.15 [0.09-0.21] 0.21 [0.16-0.24] 
Oesophagus 0.65 [0.44-0.98] 1.19 [0.74-1.57] 
Lungs 0.71 [0.59-0.89] 1.48 [1.00-1.99] 
Breasts - - 0.22 [0.12-0.30] 
Heart 0.67 [0.42-0.98] 1.47 [0.68-2.13] 
Stomach 0.16 [0.07-0.24] 0.24 [0.09-0.38] 
Liver 0.17 [0.10-0.30] 0.26 [0.19-0.42] 
Gall bladder 0.06 [0.04-0.09] 0.10 [0.07-0.13] 
Adrenals 0.14 [0.09-0.25] 0.16 [0.09-0.21] 
Spleen 0.31 [0.09-0.63] 0.44 [0.13-0.75] 
Pancreas 0.06 [0.04-0.09] 0.06 [0.03-0.08] 
Kidneys 0.06 [0.04-0.11] 0.07 [0.04-0.10] 
Small Intestine 0.02 [0.01-0.02] 0.02 [0.01-0.03] 
Colon 0.02 [0.01-0.03] 0.01 [0.01-0.01] 
Urinary bladder 0 [0-0] 0 [0-0] 
Bone marrow 0.35 [0.28-0.53] 0.53 [0.46-0.63] 
Effective dose 0.23 [0.18-0.29] 0.42 [0.29-0.53] 
 
 
Figure 4: Variation in organ dose per unit PKA with beam angle for infra-renal EVAR (cranio-caudal angle fixed at 0°). 
Figures calculated using the male ICRP phantom with a beam spectrum defined at 80 kV with 0.4 mm Cu filtration. 
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As a sensitivity analysis, simulations for the PA FEVAR/BEVAR field were repeated with a range of 
different field sizes and centring points. The ‘high’, ‘mid’ and ‘low’ fields were 40% shorter, in the 
head-foot direction, than the standard field and centred on the upper, middle and lower abdomen 
respectively. The ‘narrow’ field was the same length as the standard field but 23% narrower. The 
doses for these fields, relative to the standard field are shown in Figure 5. Doses for the narrow field 
were generally lower than for the standard field. The exception was for active bone marrow, which is 
primarily found in the spine in this region (thus receives a higher dose per unit PKA for smaller field 
size). Otherwise, ABM dose was reasonably invariant to any of the other changes. Variation in organ 
doses with centring point was consistent with organ locations, e.g. for the ‘high’ field, stomach dose 
was greater but bladder dose was much lower.  
 
Figure 5: Impact of various changes to field size, relative to the ‘standard’ field, for fenestrated EVAR. ABM = active bone 
marrow. A relative dose greater than 1.0 implies doses are higher compared to the standard field. 
 
Mean (sex averaged) effective doses calculated using PCXMC were 27, 44 and 33 mSv for IEVAR, 
FEVAR/BEVAR and TEVAR respectively, compared to 27, 54 and 37 mSv using the MCNP 
approach. The fairly large discrepancy for FEVAR/BEVAR appeared to be due to the impact of doses 
to the stomach, liver and colon, which are all higher using the MCNP approach. Figures 6-8 show the 
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relative difference in organ doses between PCXMC and MCNP. For individual procedures, the 
difference in organ dose between approaches could be large, occasionally exceeding 100%, with 
respect to MCNP. Likewise, using ‘whole procedure’ conversion factors resulted in reasonably 
similar average doses but with a large variation in dose for individual procedures (Figure 9). A 
maximum difference of +279% for the spleen occurred for a procedure in which an unusually large 
proportion of imaging was in the LAO projection, where spleen dose is reasonably low. Using the 
mean conversion factor thus grossly overestimated spleen dose for this procedure. For most organs, 
dose per unit PKA is higher in laterally orientated projections than for PA, while for bone marrow the 
reverse is true (Figure 4). Assuming all exposures were in the PA projection thus tended to result in an 
underestimation of doses by 5-15%, while bone marrow doses were overestimated by around 15% 
(Figure 10).  
 
Figure 6: Percentage difference in estimated organ doses for infra-renal EVAR procedures calculated using MCNP (with 
ICRP voxel phantoms) and PCXMC (with modified ORNL phantoms), relative to the MCNP approach. A positive difference 
means that doses calculated using PCXMC were higher than MCNP. Vertical bars represent the range of differences. The 
‘mean individual difference’ represents the mean % difference between organ doses for individual procedures 
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Figure 7: Percentage difference in estimated organ doses for fenestrated EVAR procedures calculated using MCNP with 
ICRP voxel phantoms and PCXMC with modified ORNL phantoms. A positive difference means that doses calculated using 
PCXMC were higher than MCNP. Vertical bars represent range of differences. 
 
 
Figure 8: Percentage difference in estimated organ doses for thoracic EVAR procedures calculated using MCNP with ICRP 
voxel phantoms and PCXMC with modified ORNL phantoms. A positive difference means that doses calculated using 
PCXMC were higher than MCNP. Vertical bars represent range of differences. 
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Figure 9: Mean difference in dose for infra-renal EVAR when using average conversion factors, relative to doses estimated 
using individual RDSR information. A positive difference means dose estimates were higher using average conversion 
factors. Vertical bars represent range of differences. 
 
 
Figure 10: Mean difference (black dots) in dose for infra-renal EVAR when assuming all imaging is done in the PA 
projection, relative to doses estimated using individual RDSR information. A positive difference means dose estimates are 
higher when assuming all imaging is PA. Vertical bars represent range of differences. 
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Discussion: 
In this study, we have estimated patient doses for a sample of endovascular aneurysm repair 
procedures using detailed exposure information and realistic anatomical models. Organs within the 
exposed region typically received absorbed doses of 50-100 mGy, though some procedures involved 
organ doses of several hundred mGy. Based on kerma area product, doses from EVAR are higher than 
most fluoroscopy procedure types, in which average PKA is typically less than 50 Gy cm
2 (27). A true 
comparison would require the estimation of organ doses for these other procedure types, however. 
Mean effective doses were equivalent to perhaps 3-10 single phase abdominal CT scans. However, 
these high doses must be placed in the context of the high success rate of EVAR (28), the risks from 
open surgical aneurysm repair and the risk of catastrophic haemorrhage from untreated aneurysms.  
Patients undergoing EVAR are typically aged over 70 years (e.g. (9, 29-31)). While we must assume 
these patients live long enough for radiation induced cancers to develop, risks are likely to be 
relatively small. For many of the most heavily exposed sites, including the kidneys, small intestine 
and pancreas, evidence of an association with radiation exposure is limited (32). The main risks are 
likely to be colon cancer, leukaemia, and in the case of thoracic EVAR, lung cancer. 
Average organ doses estimated using detailed exposure information from radiation dose structured 
reports were not grossly different from those either assuming a single beam angle (i.e. PA) or those 
based on average conversion factors for the whole sample of examinations. Likewise, average doses 
estimated using MCNP and realistic phantom models were reasonably similar to those obtained using 
PCXMC and stylised phantoms. This is reassuring, given that almost all previous patient dose 
estimates for EVAR have used PCXMC (e.g. (5, 9, 29-31)). Large differences were found for 
individual procedures, however, meaning the use of PCXMC or the 𝐶𝐹𝑃𝐾𝐴→𝐷 conversion factors 
presented in Tables 6-8 may be better suited to non-individualised purposes such as audits. 
Differences between dose estimates obtained using MCNP/ICRP and PCXMC/ORNL approaches 
may be due to (1) the lack of male/female specific phantoms in PCXMC, (2) the inability to directly 
model in PCXMC table attenuation and backscatter of x-rays by the table, (3) differences in organ 
shapes and locations, (4) different particle interaction cross section libraries, and (5) different x-ray 
spectra generation methods (14). The first three explanations likely dominate the observed 
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differences. For beams passing through the table, a reduction in intensity of ≈20% occurs. Conversely, 
the use of female phantoms, as opposed to male, results in an approximately 30% increase in dose 
(though this varied considerably between organs). Where PCXMC is used, the input PKA could be 
reduced to account for table attenuation prior to simulation, while the phantom representing a 15-year 
old individual may give a better approximation of female doses than the standard adult phantom.  
To our knowledge, only a single previous study has estimated organ doses from EVAR procedures. 
Blaszak and Juszkat (33) used the dose estimation tool CalDose_X (the only previous study to not use 
PCXMC-derived patient dose estimates). CalDose_X (34) is a free lookup-table based application, 
which uses conversion factors previously obtained from Monte Carlo simulations. The dose estimates 
of Blaszak and Juszkat are based on the anterior-posterior (AP) projection, while the PA projection 
was the dominant beam angle in our study (there were no AP exposures listed in the RDSRs). As 
expected, considering the difference in beam angles, estimated doses for anterior lying organs (e.g. 
stomach, bladder) are much lower in the current study, while doses for posterior lying organs (e.g. 
kidneys) are much higher.  
 
Errors and uncertainties: 
In this study, we used a lookup table approach to estimate patient doses, as opposed to performing 
‘live’ Monte Carlo simulations for each exposure listed in RDSRs. The advantage of the lookup table 
approach is greatly increased computational speed. The sample of 183 examinations involved over 
44,000 individual exposures. Performing MC simulations for each of these would take several 
months, while the lookup table approach allowed doses to be estimated within 10 minutes. The main 
disadvantage of this approach is lack of flexibility, with dose estimates restricted to conditions under 
which conversion factors were calculated. 
Type-A uncertainties resulting from the finite number of particles tracked in Monte Carlo simulations 
were kept below 5% for all individual organs reported in this paper, and usually below 1%. Type-B 
uncertainties due to source geometry and energy spectra were reduced substantially through the use of 
radiation dose structured reports. Without utilising detailed beam angle information (assuming all 
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imaging was in the PA projection) we estimate organ dose uncertainties to be ±50%, based on the 
ranges shown in Figure 9.  
We were unable to utilise some of the information from the radiation dose structured reports, 
including field size and beam centring point. Although a methodology for determining centring points 
from RDSRs has been developed (35) and implemented (24), incorporating different centring points 
would require calculation of new sets of lookup tables, thus requiring a lot of extra work. 
Furthermore, the region of interest in EVAR is less well defined than for other fluoroscopy 
procedures in which the above-mentioned methods (35) were developed. The results of the sensitivity 
analysis suggest that field size and centring point uncertainties are highly organ specific. We estimate 
uncertainties associated with field size and centring point to be ±10% for bone marrow, ±30% for 
colon and effective dose and ±50% for other organs (Figure 5). 
Errors are introduced by the use of HVL to represent x-ray beam spectra. This is because the same 
HVL can be produced by different combinations of tube potential and filtration, while these different 
combinations yield different patient dose, per unit PKA. At high HVLs (>7 mm Al), these errors are 
very small (<5 %), though may exceed 20% as the HVL is decreased below around 4 mm Al. 
A further source of uncertainty is the phantom models used in Monte Carlo simulations. Although the 
ICRP male and female voxel phantoms are more anatomically realistic than the stylised models used 
in PCXMC, differences between phantom and individual patient anatomy will still introduce errors in 
dose estimates. Our simulations were based on adults of reference size, while in reality some are 
obese (11). Increased adipose tissue thickness requires increased x-ray output to maintain signal-to-
noise ratio, while decreasing organ dose per unit x-ray output (36). The former effect is taken into 
account in the form of increased PKA, while the latter is not. Consequently, organ doses for obese 
patients are likely to be overestimated in our study.  
Differences in atomic composition of organs, blood and other fluids between real patients and 
phantoms will also result in errors, especially at low photon energies. The study did not incorporate 
the impact of iodinated contrast media (ICM), which is used in EVAR procedures to improve 
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visualisation of blood vessels. Previously we have shown that ICM can markedly increase absorbed 
dose to the endothelium of blood vessels for enhanced x-ray exposures (37) by acting as a source of 
secondary electrons. The lining of the aorta itself may therefore receive especially high doses from 
EVAR. Overall, ICM appears to result in a moderate increase in dose to organs and tissues (38), 
although this effect is highly dependent on iodine concentration in the main blood vessels, capillaries 
and interstitial tissues (37). Including the impact of iodine is extremely challenging, however, due to 
difficulties in determining iodine concentration in both major vessels and in the capillary network and 
interstitial space of organs. 
 
Conclusion: 
In this study, we have produced state-of-the-art estimates of patient doses from x-ray guided 
endovascular aneurysm repairs, utilising realistic anatomical models and detailed information on 
beam angles and x-ray energy. Patient doses from EVAR are generally high, though this is justified 
given the life sparing nature and high success rate of the procedure. 
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Appendix 1: Details of Monte Carlo methodology 
 
Name of Monte Carlo code MCNPX V 2.7 
Cross section library ENDF/B-VII 
Source description Photon point source. Isotropic with forward biasing. Energy 
spectrum in 1 keV bins. 
Variance reduction Not used 
Approximate efficiency 
improvement techniques 
Not used 
Number of histories 107 (approx. 5-15 minutes computing time) 
Step size ESTEP set at 3 (default value) 
Scored parameters Absorbed dose in MeV/g to phantom organ cells and PKA meter 
cell using f6 tally 
Normalisation Organ dose tally divided by PKA meter tally multiplied by beam 
area at collimator window. 
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Appendix 2: Detailed description of voxel phantom models and other materials used 
in simulations 
 
General characteristics: 
Characteristic 
Phantom 
Male Female 
Height (cm) 176 163 
Mass (kg) 73 60 
Voxel volume (mm³) 36.5 15.3 
Arms (Y/N) N N 
 
Material composition and density: 
Male phantom: 
Tissue/ material 
Chemical composition (%) Density 
(g/cm³) H-1 C-6 N-7 O-8 Na-11 Mg-12 P-15 S-16 Cl-17 K-19 Ca-20 Fe-26 I-53 
Bone 3.6 15.9 4.2 44.8 0.3 0.2 9.4 0.3     21.3     1.92 
Muscle 10.2 14.2 3.4 71.1 0.1   0.2 0.3 0.1 0.4       1.05 
Skin 10.0 19.9 4.2 65.0 0.2   0.1 0.2 0.3 0.1       1.09 
Blood 10.2 11.0 3.3 74.5 0.1   0.1 0.2 0.3 0.2   0.1   1.06 
Liver 10.2 13.0 3.4 72.5 0.2   0.2 0.3 0.2 0.3       1.05 
Pancreas 10.5 15.5 2.5 70.6 0.2   0.2 0.1 0.2 0.2       1.05 
Brain 10.7 14.3 2.3 71.3 0.2   0.4 0.2 0.3 0.3       1.05 
Heart 10.4 13.8 2.9 71.9 0.1   0.2 0.2 0.2 0.3       1.05 
Eyes 9.7 18.1 5.3 66.3 0.1   0.1 0.3 0.1         1.05 
Kidneys 10.3 12.4 3.1 73.1 0.2   0.2 0.2 0.2 0.2 0.1     1.05 
Stomach 10.5 11.4 2.5 75.0 0.1   0.1 0.1 0.2 0.1       1.04 
Small intestine 10.5 11.3 2.6 75.0 0.1   0.1 0.1 0.2 0.1       1.04 
Large intestine 10.5 11.3 2.6 75.0 0.1   0.1 0.1 0.2 0.1       1.04 
Spleen 10.2 11.1 3.3 74.3 0.1   0.2 0.2 0.3 0.2   0.1   1.04 
Thyroid 10.4 11.7 2.6 74.5 0.2   0.1 0.1 0.2 0.1     0.1 1.04 
Bladder 10.5 9.6 2.6 76.1 0.2   0.2 0.2 0.3 0.3       1.04 
Testes 10.6 10.0 2.1 76.4 0.2   0.1 0.2 0.2 0.2       1.04 
Adrenals 10.4 22.1 2.8 63.7 0.1   0.2 0.3 0.2 0.2       1.03 
Oesophagus 10.4 21.3 2.9 64.4 0.1   0.2 0.3 0.2 0.2       1.03 
Gall bladder 10.4 23.1 2.8 62.7 0.1   0.2 0.3 0.2 0.2       1.03 
Prostate 10.4 23.1 2.8 62.7 0.1   0.2 0.3 0.2 0.2       1.03 
Lymph 10.8 4.2 1.1 83.1 0.3     0.1 0.4         1.03 
Breast 11.2 51.6 1.1 35.8 0.1     0.1 0.1         1.02 
Adipose 11.4 58.8 0.8 28.7 0.1     0.1 0.1         0.95 
Lungs 10.3 10.7 3.2 74.6 0.2   0.2 0.3 0.3 0.2       0.42 
GI tract contents 10.0 22.2 2.2 64.4 0.1   0.2 0.3 0.1 0.4 0.1     1.04 
Urine 10.7 0.3 1.0 87.3 0.4   0.1     0.2       1.04 
 
% of all other elements is zero. 
 
 
 
 
Page 27 of 29 AUTHOR SUBMITTED MANUSCRIPT - JRP-101891.R2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 Ac
c
pte
d M
an
us
cri
pt
28 
 
Female phantom: 
Tissue/ material 
Chemical element Density 
(g/cm³) H-1 C-6 N-7 O-8 Na-11 Mg-12 P-15 S-16 Cl-17 K-19 Ca-20 Fe-26 I-53 
Bone 3.6 15.9 4.2 44.8 0.3 0.2 9.4 0.3     21.3     1.92 
Muscle 10.2 14.2 3.4 71.1 0.1   0.2 0.3 0.1 0.4       1.05 
Skin 10.0 19.9 4.2 65.0 0.2   0.1 0.2 0.3 0.1       1.09 
Blood 10.2 11.0 3.3 74.5 0.1   0.1 0.2 0.3 0.2   0.1   1.06 
Liver 10.2 13.1 3.1 72.4 0.2   0.2 0.3 0.2 0.3       1.05 
Pancreas 10.5 15.7 2.4 70.5 0.2   0.2 0.1 0.2 0.2       1.05 
Brain 10.7 14.4 2.2 71.3 0.2   0.4 0.2 0.3 0.3       1.05 
Heart 10.4 13.8 2.9 71.9 0.1   0.2 0.2 0.2 0.3       1.05 
Eyes 9.7 18.3 5.4 66.0 0.1   0.1 0.3 0.1         1.05 
Kidneys 10.3 12.5 3.1 73.0 0.2   0.2 0.2 0.2 0.2 0.1     1.05 
Stomach 10.5 11.4 2.5 75.0 0.1   0.1 0.1 0.2 0.1       1.04 
Small intestine 10.5 11.4 2.5 75.0 0.1   0.1 0.1 0.2 0.1       1.04 
Large intestine 10.5 11.4 2.5 75.0 0.1   0.1 0.1 0.2 0.1       1.04 
Spleen 10.3 11.2 3.2 74.3 0.1   0.2 0.2 0.2 0.3       1.04 
Thyroid 10.4 11.8 2.5 74.5 0.2   0.1 0.1 0.2 0.1     0.1 1.04 
Bladder 10.5 9.6 2.6 76.1 0.2   0.2 0.2 0.3 0.3       1.04 
Ovaries 10.5 9.4 2.5 76.6 0.2   0.2 0.2 0.2 0.2       1.04 
Adrenals 10.4 22.8 2.8 63.0 0.1   0.2 0.3 0.2 0.2       1.03 
Oesophagus 10.4 22.2 2.8 63.6 0.1   0.2 0.3 0.2 0.2       1.03 
Gall bladder 10.5 23.5 2.8 62.2 0.1   0.2 0.3 0.2 0.2       1.03 
Uterus 10.5 28.6 2.5 57.6 0.1   0.2 0.3 0.1 0.2       1.03 
Lymph 10.8 4.2 1.1 83.1 0.3     0.1 0.4         1.03 
Breast 11.2 51.6 1.1 35.8 0.1     0.1 0.1         1.02 
Adipose 11.4 58.9 0.7 28.7 0.1     0.1 0.1         0.95 
Lungs 10.3 10.7 3.2 74.6 0.2   0.2 0.3 0.3 0.2       0.42 
GI tract contents 10.0 22.2 2.2 64.4 0.1   0.2 0.3 0.1 0.4 0.1     1.04 
Urine 10.7 0.3 1.0 87.3 0.4   0.1     0.2       1.04 
 
Other materials: 
Tissue/ 
material 
Chemical element Density 
(g/cm³) H-1 C-6 N-7 O-8 Na-11 Mg-12 P-15 S-16 Cl-17 K-19 Ca-20 Fe-26 I-53 
Air     80.0 20.0                   0.0013 
Bed   100.0                       1.40 
 
 
 
 
 
 
 
 
Page 28 of 29AUTHOR SUBMITTED MANUSCRIPT - JRP-101891.R2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 Ac
ce
pte
d M
an
us
cri
pt
29 
 
Coronal plane images of male (left) and female (right) phantoms at the level of the kidneys 
(male/female images are not to same scale) 
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